17
Participants
Start Date
January 31, 2010
Primary Completion Date
August 31, 2014
Study Completion Date
September 30, 2016
Azacitidine
Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
Virginia Commonwealth University, Richmond
Collaborators (1)
National Cancer Institute (NCI)
NIH
Celgene Corporation
INDUSTRY
Virginia Commonwealth University
OTHER